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Abstract. Background/Aim: Extraordinary restrictions aimed
to limit Sars-CoV-2 spreading; they imposed a total
reorganization of the health-system. Oncological treatments
experienced a significant slowdown. The aim of our multicentric
retrospective study was to evaluate screening suspension and
surgical treatment delay during COVID-19 and the impact on
breast cancer presentation. Patients and Methods: All patients
who underwent breast surgery from March 11, 2020 to May 30,
2020 were evaluated and considered as the Lockdown group.
These patients were compared with similar patients of the
previous year, the Pre-Lockdown group. Results: A total of 432
patients were evaluated; n=223 and n=209 in the Lockdown
and Pre-lockdown-groups, respectively. At univariate analysis,
waiting times, lymph-nodes involvement and cancer grading,
showed a statistically significant difference (p<0.05).
Multivariate analysis identified waiting-time on list (OR=1.07)
as a statistically significant predictive factor of lymph node
involvement. Conclusion: Although we did not observe a
clinically evident difference in breast cancer presentation, we
reported an increase in lymph node involvement.
Sars-CoV-2 infection has dramatically spread worldwide
since the beginning of 2020 (1). Due to rapid human-to-
human transmission and in order to limit the viral spread, on
March 10, 2020, the government has implemented
extraordinary restrictions (2). These measures changed our
daily routine and forced a reorganization of the Health
system (3). During the pandemic, especially at the beginning
of the lockdown, only urgent medical services were
guaranteed while oncological diagnostic procedures and
treatments suffered a significant slowdown (3). Many
national and international scientific societies and research
groups published recommendations aiming to prioritize
breast cancer management strategies, preserve hospital
resources for COVID-19 and reduce the risk of cross-
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infection (4-6). Regardless of the recommendations, breast
cancer screening programs were temporarily suspended (7).
Even though breast cancer is the most common cancer in
women worldwide, in the last years there has been a
decrease in mortality (8). Additionally, invasive breast
surgeries (e.g. mastectomy) have decreased along the years.
Both these favourable outcomes have been made possible
partially thanks to the improvement in early breast cancer
diagnosis achieved by the screening programs (9). Many
researches have reported that in addition to the improvement
in survival, there is a significant reduction in breast cancer
diagnosed by physical examination (e.g. palpable lesion) (7,
10-12). We hypothesized that screening suspension and
surgical treatment delay could alter the clinical presentation
and features of breast cancer.
The aim of our multicentric retrospective study was to
evaluate the impact of screening suspension and treatment
delay during the COVID-19 lockdown, on breast cancer
clinical presentation, diagnosis and surgical treatments.
Patients and Methods
Study design. In our multicentric study we retrospectively analyzed
data from four Italian Brest Units: “Azienda Ospedaliero-
Universitaria Policlinico” hospital of Modena, “Gulielmo da Saliceto”
hospital Piacenza, Tor Vergata University Hospital Rome and Campus
Bio-Medico University hospital Rome. All patients who underwent
breast surgery from March 11, 2020 to May 30, 2020 were evaluated
in our study and were considered as the Lockdown group. These
patients were compared with patients who undergone breast surgery
during the same period of the previous year (March 11, 2019 to May
30, 2019), defined as the Pre-Lockdown group. 
Four hundred and thirty-two (n=432) patients were evaluated in
the study. Patients who did not undergo oncological surgery were
excluded from the analysis. The manuscript was approved by the
local Ethical Committee of the Fondazione Policlinico Tor Vergata
(reference 122/20).
Variable and outcome definition. The number of surgical procedures
performed by each Breast Unit during the studied periods were
reported. For each patient, date of diagnosis, admission, surgery and
discharge were collected. 
Preoperative diagnosis was obtained through cytological
examination or biopsy as core needle biopsy or Vacuum assisted
biopsy. 
Waiting time on list was reported in days, defined as the time
between histological or cytological examination and date of surgery.
Data regarding age and prior administration of neoadjuvant
chemotherapy were collected from clinical notes. Reoperation was
recorded when a second surgery was performed within 3 months
from the primary procedure. 
Surgical procedures were distinguished between breast
conservative surgery and breast invasive surgery. Breast
conservative surgery included all procedures with a partial gland
removal. Alternatively, breast invasive surgery comprised the
complete removal of the glandular tissue with or without sparing
the nipple areola complex (mastectomy). Preoperative image-guided
wire localization was reported for breast conservative surgery cases. 
The axillary procedure was analysed as well. Patients without
clinical or radiological evidence of lymph nodes involvement
underwent sentinel lymph node biopsy (SLNB). Otherwise, patients
with axillary involvement or SLNB positivity underwent axillary
lymph node dissection (ALND). Number of nodes removed during
ALND and the degree of node involvement within specimens were
reported and analyzed. Length of hospital stay was reported in days,
considered as the time between hospital admission and discharge.  
Data from surgical specimens were included in the study. Tumor
maximum diameters were collected and reported in millimetres.
Pathological staging was based on recommendations from AJCC
2018 (edition VIII) for TNM classification. Tumor grading was
evaluated according to the Nottingham Histologic Score system (the
Elston-Ellis modification of Scarff-Bloom-Richardson grading
system). Estrogen receptor (ER), Progesterone receptor (PR) and
Ki67 index were expressed as percentage of positive cells in the
specimens studied through immunohistochemistry. Overexpression
of Her2 gene (HER2+) was identified by immunohistochemistry or
by fluorescent in situ hybridization (FISH), as indicated by the
recommendations of the 2018 ASCO/CAP, reported as a
dichotomous variable (HER+ yes/no). 
Statistical analysis.All data were collected into the EXCEL database
(Microsoft, Washington, DC, USA). For continuous variables, we
calculated medians and ranges. The t-test was used to determine
whether there were significant differences between the two groups.
Categorical data were recorded in numbers and percentages. Analysis
was performed using the Fisher’s exact test in case of dichotomous
variables or Monte Carlo test for non-dichotomous variables.
Variables with assigned p-values <0.05 were considered statistically
significant. Cox regression was used for multivariate analysis. All the
statistical analysis was performed in SPSS statistical package version
23.0 (SPSS Inc., Chicago, IL, USA). 
Results
From March 11, 2020 to May 30, 2020 a total of 223 patients
underwent breast surgery (Lockdown group) compared to 209
treated in the same period of the previous year (Pre-Lockdown
group). Twenty patients of the Lockdown group (8.9%)
underwent non-oncological surgery (reconstructive) and were
excluded from the analysis. Accordingly, 37 cases of the Pre-
Lockdown group (17.9%) were excluded as well, p<0.05.
Median age was 62 [35-90] years in the Lockdown group
and 60.8 [21-89] years in the Pre-lockdown group, p=0.196.
Among the Lockdown group, preoperative diagnosis
assessment was performed in 32 cases by cytological
examination (15.7%) and in 187 by biopsy (92.1%). In the
Pre-Lockdown group, 24 (13.9%) patients underwent
cytological examination and 159 (92.4%) were biopsied. Both
variables did not show any statistically significant difference
with p-values of 0.066 and 1.000, respectively. Upon specimen
examination, 48 (27.9%) patients presented with in situ breast
carcinoma in the Lockdown group vs. 24 (18.9%) in the
control group, p=0.065. Twenty-eight (13.8%) patients
presented ipsilateral node involvements in the Lockdown vs.
19 (11.4%) patients in the Pre-Lockdown group, p=0.439.
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Administration of neoadjuvant therapy was carried out in 19
patients (9.3%) in the Lockdown group and in 16 patients
(9.3%) in the Pre-Lockdown group, with no statistically
significant difference, p=1.000. Waiting time on list, the time
between biopsy/cytological examination and surgery, was
shorter in the Pre-Lockdown group: mean values of 42 [10-
220] days vs. 56 [6-134] days, showing a statistically
significant difference, p<0.05. However, waiting time on list
adjusted for other factors was the only factor exhibiting an
increased risk for nodes involvement when analysed as a
dichotomous variable in a logistic binary regression. 
Breast conservative surgery was performed in 141 (69.5%)
patients in the Lockdown group, and 100 (71%) of these
cases required preoperative image-guided wire localization.
In the Pre-Lockdown group, 121 (70.3%) cases underwent
breast conservative surgery and wire localization was
required in 70 (57.9%) of them. Both these parameters did
not show any statistically significant difference p=0.6491
and p=0.060, respectively. Types of surgery and relative p-
values are shown in Table I. 
SNLB was performed in 175 (86.2%) cases in the
Lockdown group and 30 (17.1%) cases were found positive
for cancer at frozen section examination. In the Pre-Lockdown
group, 153 patients (87.9%) underwent SNLB and cancer was
recorded in 14 cases (9.1%). Incidence of lymph nodes
positivity through SNLB showed a statistically significant
difference, p=0.035. Conversely, indications for SNLB did not
show statistical significance, p=0.647 (Table I).
ALND was performed in 58 (28.6%) patients in the
Lockdown group, compared to 33 cases (20.0%) in the
control group, showing a statistically significant difference
with p=0.039. Indications for ALND are presented in Table
I. Number of lymph nodes removed during ALND and
number of negative results at pathological examination did
not exhibit statistically significant differences between the
groups with respective p-values of 0.499 and 0.495. 
Length of hospital stay was comparable between the
groups without showing a statistically significant difference,
p=0.436. Median hospitalization time was 2 days (range=0-
91 days) in the Lockdown and 2 days (range=0-93 days) in
the Pre-Lockdown group.
At pathological examination of Lockdown group, 145
(63%) cases were determined as ductal carcinoma, 32
(15.8%) as lobular carcinoma and 26 (11.3%) were defined
as others. In the Pre-Lockdown group, 133 (76%), 20
(11.5%) and 18 (9.7%) were determined as ductal
carcinoma, lobular carcinoma and others, respectively. No
statistically significant differences were found, and the p
values were 0.292, 0.294 and 0.0196, respectively. One
hundred and fifty (74%) cases of the Lockdown group were
invasive carcinoma vs. 137 (78%) in the control group,
(p=0.278).
Maximum diameter of lesions did not show a statistically
significant difference between the groups, p=0.323. Median
tumor diameters were 12 mm (range=6-80 mm) in the
Lockdown group and 13 mm (range=4-90 mm) in the
control group. T distribution between the groups did not
show a statistically significant difference, p=0.489, depicted
in Table II.
Lymph node involvement exhibited a statistically
significant difference between the groups (p=0.031),
grading of the involvement is presented in Table II. The
Lockdown group exhibited higher incidence of
N2compared to the Pre-Lockdown group (8% vs. 2%), and
the difference was statistically significant with p<0.05.
Four patients (1.97%) presented with metastatic breast
cancer disease in the Lockdown group compared to 1 case
(0.58%) in the Pre-Lockdown group, p=0.380. Pathological
specimen prognostic and predictive factors are shown in
Table III. All these variables did not show statistically
significant differences. Nonetheless, tumor grading was
different among the groups (p=0.032) and its distribution
is depicted in Table III. 
Incidence of reoperation was comparable in the two
groups (p=0.512) with 25 (12%) and 17 (10%) cases in
Lockdown and Pre-lockdown groups, respectively. At
logistic binary regression, waiting time was the variable
associated with increased risk for lymph nodes involvement
(univariate p=0.008). Differently, tumor grading was not a
statistically significant factor for predicting lymph nodes
major involvement, p=0.208. Other factors analyzed with
logistic regression are presented in Table IV. Multivariate
logistic regression analysis identified waiting time on list
(considering 10 days) (OR:1.07) as a statistically significant
factor (p=0.017), predictive of lymph nodes major
involvement. Other factors analyzed by multivariate analysis
are depicted in Table IV. 
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Table I. Distribution of type of surgery between groups.
                                             Lockdown          Pre-lockdown       p-Value
                                                 group                     group
                                                (n=203)                  (n=172)
Mastectomy                         62 (30.5%)             45 (26.2%)           0.361
Conservative Surgery        141 (69.5%)           121 (70.3%)           0.649
  Wire localization             110 (71%)                70 (57.9%)           0.060
SNLB                                 175 (86.2%)           153 (87.9%)           0.647
  SNLB positive                   30 (17.1%)             14 (9.1%)             0.035
ALND                                  58 (28.6%)             33 (20.0%)           0.039
  ALND N+                          28 (48.3%)             19 (57.6%)           0.513
  ALND SNLB positive      30 (51.7%)             14 (42.4%)           0.513
SNLB: Sentinel lymph node biopsy; ALND: axillary lymph nodes
dissection; ALND SNLB positive: axillary lymph nodes found positive
after sentinel lymph node at frozen sections. Bold values indicate
statistical significance.
Discussion
The spread of Sars-CoV2 reached pandemic dimensions in the
last months with around 43 million infections worldwide (13).
Due to rapid human transmission and in order to limit viral
spread, many countries are implementing severe restrictions
(2). These measures have altered our daily routine and forced
a reorganization of the Health system (3). Accordingly, this
reorganization includes resources reallocation toward COVID-
19 as well as temporary suspension of non-urgent medical
services (3). Especially at the beginning of the lockdown,
oncological procedures suffered a significant slowdown (3).
In this regard, most routine oncological preventive activities
were suspended (6). Although the number of COVID-19 cases
in Italy is decreasing and despite the return to routine life,
breast cancer screening programs are still temporarily scaled
down (2-7).
Although breast cancer is the most frequent cancer and
represents the leading cause of oncological death among women
worldwide; latest statistics suggest that there has been an
improvement in term of prognosis (14, 15). Both, empowerment
of breast cancer treatments and higher incidence of early
diagnosis, due to the screening, have led to this improvement
(9-16). The benefits of screening are largely attributed to the
ability to diagnose breast cancer in earlier stages (17). This is a
fundamental factor responsible for reducing recurrence and
demolitive surgery and increasing survival rate (18).
Absolute number of surgical procedures during the
COVID-19 outbreak are comparable with the same period of
the previous year (2019). According to the restrictive
measures and scientific recommendations, we observed a
significant reduction in non-oncological surgical procedure
(reconstructive surgery) (6, 7, 19, 20). During the lockdown,
most national and international guidelines recommended that
reconstruction procedures should be deferred (21, 22).
Waiting lists for breast reconstructive surgery could become
clogged and would bring about a psychological impact on
women’s quality of life (23). In order to avoid further delays,
physicians have increased the number of oncological surgical
procedures (24, 25). In fact, the number of oncological
procedures was higher during the lockdown.
Waiting time on list and the time between biopsy/
cytological examination to surgery were significantly longer
in the Lockdown group. This delay can be attributed to the
slowdown of oncological treatments during the lockdown
due to the Health system reorganization and resources
reallocation (3). Additionally, patients’ anxiety and treatment
refusals could have contributed to the delay (26).   
Despite breast cancer screening suspension, we did not
observe an increase in primary tumor dimensions calculated as
maximum diameter and relative T stage of the disease. In
accordance with this result, incidence of mastectomy and
conservative breast surgery without radiological wire
localization (palpable lesions) were comparable between the
two groups. Many Italian studies have reported a reduction in
breast cancer diagnosed by physical examination as well as in
mastectomies due to early detection through screening (15, 27,
28). The short timeframe between the screening suspension and
our analysis could explain this result. In fact, the time between
diagnosis assessment and surgery is longer than 1 month. Thus,
in the coming months we could probably observe tumors with
larger dimensions or more clinically evident. 
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Table III. Prognostic and predictive factors between groups.
                                             Lockdown          Pre-lockdown       p-Value
                                                 group                     group
                                                (n=203)                  (n=172)                   
Diameters                             12 mm [6-80]        13 mm [4-90]       0.323
ER                                         79% [0-100]          78% [0-100]        0.305
PR                                         54% [0-100]          52% [0-100]        0.352
Ki67                                      15% [1-80]            16% [3-80]          0.054
Grading                                                                                             0.032
  G1                                      27 (13.3%)             37 (21.5%)                
  G2                                    100 (49.2%)             65 (37.8%)                
  G3                                      52 (25.6%)             36 (20.9%)                
HER2                                                                                                0.698
Negative                               77 (38.1%)             70 (40.7%)                
  Score 1                               54 (26.7%)             51 (29.65%)              
  Score 2                               10 (5%)                    5 (2.9%)                  
  Score 3                               11 (5.4%)                 8 (4.6%)                  
Table II. TNM distribution between groups with relative p-values,
absolute numbers and (percentages).
                                             Lockdown          Pre-lockdown       p-Value
                                                 group                     group
                                                (n=203)                  (n=172)
T                                                                                                        0.493
  T is                                     26 (12.8%)             15 (8.7%)                  
  T1                                     131 (64.5%)           112 (65.8%)                
  T2                                       31 (15.3%)             36 (20.9%)                
  T3                                         9 (4.4%)                 4 (2.3%)                  
  T4                                         3 (1.5%)                 3 (1.7%)                  
N                                                                                                       0.031
  N0                                    121 (59.1%)           105 (60.3%)                
  N1                                      24 (11.8%)              21(12.2%)                
  N2                                      16 (8%)                    4 (2.3%)                  
  N3                                        3 (1.5%)                 5 (2.8%)                  
M                                                                                                       0.380
  M0                                    199 (98%)              173 (99.4%)                
  M1                                        4 (2%)                    1 (0.6%)                  
T: Tumor; N: lymph nodes; M: metastasis. Bold values indicate
statistical significance.
During the lockdown, we observed a reduction in incidence
of well differentiated tumors. Apparently, tumors with higher
grading are lesions with rapidly changing clinical features that
may reveal themselves earlier and alert patients and physicians
(29, 30). Conversely, lesions with stable clinical features
associated with COVID-19 anxiety may have led to the
reduction of well differentiated breast cancer incidence during
the outbreak (24-31). In the next months, we may observe low
grading lesions but probably in an advanced local stage.
Malignant lymph nodes involvement seems to be more
frequent among the Lockdown group. We observed a
significantly greater number of sentinel lymph nodes positive
for cancer during the COVID-19 outbreak. In concordance
with this result, incidence of ALND was significantly higher
in the lockdown group. N staging distribution seems to be
more advanced in the lockdown group with incidence of N2
being significantly higher (32, 33). Involvement and number
of positive lymph nodes are prognostic factors of breast
cancer (34-38). The higher incidence of nodes involvement
and local advanced stage could be partially related to the
screening suspension and delayed diagnosis (6). Additionally,
we observed a different distribution of cancer grades, which
could also be partially correlated with lymph nodes advanced
stages (26-39). Nonetheless, at multivariate analysis, waiting
time on list, significantly longer during the Lockdown, seems
to be the only predictive factor of lymph nodes involvement
progression. According to our results, the oncological
slowdown caused by the Covid-19 lockdown, patients’
anxiety and breast cancer screening suspension lead to an
increase in lymph nodes advanced stages.
Conclusion
The results of breast cancer screening suspension and
oncological surgical treatment delay during these months are
not yet clinically evident. We reported an increase in
pathological nodes involvement. Furthermore, in the comings
months we might also observe an increase in tumor dimensions
and incidence of clinically evident lesions with a consequent
increase of post-surgery treatments and worse quality of life.  
The benefit of screening is largely attributed to the ability
to diagnose breast cancer in earlier stages and improve
prognosis. Breast cancer screening suspension and surgical
treatments delay, due to Covid-19 lockdown, could impact
breast cancer presentation and staging. We did not observe
a clinically evident difference in breast cancer presentation
due to screening suspension and oncological treatments
delay. We report an increase in lymph nodes involvement.
The most significant factor predictive of major advanced N
stage was the waiting time on list. In the coming months,
we might also observe an increase in tumor dimensions and
incidence and clinically evident lesions with a consequent
worsening of quality of life. This study highlighted the
importance of maintaining breast cancer screening programs
and avoiding oncological treatment delays. This could
impact clinical staging of breast cancer presentation,
treatments, prognosis and quality of life of women.
Resource reallocation should also take these aspects into
consideration in the event of new lockdown due to second
COVID-19 wave spread.
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Table IV. Predictive factors of lymph node involvement. Univariate and multivariate analysis.
                                                                                        Univariate                                                                                  Multivariate                        
Predictive factors                              OR                           95%CI                         p-Value                      OR                        95%CI                      p-Value
Waiting time (10 days)                   1.07                        1.01-1-13                         0.008                       1.07                     1.01-1.13                      0.017
Tumor grading                                 1.16                         0.83-1.64                         0.371                                                                                         0.208
Patient age                                        1.00                         0.98-1.01                         0.951                                                                                         0.139
Period of surgery                            1.062                       0.70-1.60                         0.776                                                                                         0.781
OR: Odds ratio; CI: confidence interval. Bold values indicate statistical significance.
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